Phosphoric Acid

Phosphoric Acid

SCHEMBL736397

O.O.O.O.O.O.O=P([O-])([O-])[O-].[Na+].[Na+].[Na+]

nearest known ligand 0.43

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

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

The experimentally established mechanism targets of Phosphoric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
LMNA P02545 4/20 0.43
SLC34A1 Q06495 1/20 0.42
KDM4E B2RXH2 1/20 0.35
CYP2C19 P33261 1/20 0.35
KMT2A Q03164 1/20 0.35
CA1 P00915 2/20 0.33
CA4 P22748 2/20 0.33
CA5A P35218 2/20 0.33
CA5B Q9Y2D0 2/20 0.33
BLM P54132 1/20 0.32
PMP22 Q01453 1/20 0.32
CYP2C9 P11712 1/20 0.32
TSHR P16473 1/20 0.32
ALOX12 P18054 1/20 0.32
NFKB1 P19838 1/20 0.32
MAPK1 P28482 1/20 0.32
SMN1; SMN2 Q16637 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Phosphoric Acid SCHEMBL122808 1.00 LMNA (0.43) LMNASLC34A1KDM4ECYP2C19KMT2A
Phosphoric Acid SCHEMBL1396195 1.00 LMNA (0.43) LMNASLC34A1KDM4ECYP2C19KMT2A
Phosphoric Acid SCHEMBL735586 1.00 LMNA (0.43) LMNASLC34A1KDM4ECYP2C19KMT2A
Phosphoric Acid SCHEMBL1076271 1.00 LMNA (0.43) LMNASLC34A1KDM4ECYP2C19KMT2A
Phosphoric Acid SCHEMBL156385 1.00 LMNA (0.43) LMNASLC34A1KDM4ECYP2C19KMT2A
Phosphoric Acid SCHEMBL1804580 1.00 LMNA (0.43) LMNASLC34A1KDM4ECYP2C19KMT2A
Phosphoric Acid SCHEMBL734680 1.00 LMNA (0.43) LMNASLC34A1KDM4ECYP2C19KMT2A
Phosphoric Acid SCHEMBL232957 1.00 LMNA (0.43) LMNASLC34A1KDM4ECYP2C19KMT2A
Phosphoric Acid SCHEMBL2020039 1.00 LMNA (0.43) LMNASLC34A1KDM4ECYP2C19KMT2A
Phosphoric Acid SCHEMBL14760076 1.00 LMNA (0.43) LMNASLC34A1KDM4ECYP2C19KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 184 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-122005864-A Adeno-associated viral vector pharmaceutical compositions and methods 再生生物股份有限公司 2026-05-12 CN claimed
US-20250333578-A1 COMPOSITION MADE FROM POLY(ARYLENE-ETHER-KETONE) (PAEK) WHICH IS STABLE IN THE MOLTEN STATE AND METHOD FOR STABILIZING SUCH A COMPOSITION ARKEMA FRANCE (FR) 2025-10-30 US claimed
EP-3507246-B1 PREPARATION PROCESS FOR POTASSIUM CHLORIDE GRANULATES K S AG (DE) 2025-07-16 EP claimed
CN-119143482-A Tundish slag line dry material 上海利尔耐火材料有限公司 2024-12-17 CN claimed
CN-113088062-B Method for stabilizing a composition made of poly (arylene-ether-ketone) (PAEK) 阿科玛法国公司 2024-07-02 CN claimed
EP-3325536-B1 PROCESS FOR STABILIZING A COMPOSITION OF POLYARYL-ETHER-KETONE (PAEK) ARKEMA FRANCE (FR) 2024-06-26 EP claimed
US-20240108669-A1 ADENO-ASSOCIATED VIRUS VECTOR PHARMACEUTICAL COMPOSITION AND METHODS REGENXBIO INC. 2024-04-04 US claimed
CN-107250318-B Super concentrate additive solution compositions 布拉斯通产品公司 2023-10-27 CN claimed
CN-116536032-A Composition for preparing high-heat-conductivity composite phase-change material, and preparation method and application thereof 佛山市顺德区美的饮水机制造有限公司 2023-08-04 CN claimed
EP-4041292-A1 ADENO-ASSOCIATED VIRUS VECTOR PHARMACEUTICAL COMPOSITION AND METHODS RegenxBio Inc. (US) 2022-08-17 EP claimed
CN-107849238-A Method for stabilizing compositions made from poly (arylene-ether-ketones) (PAEKs) 阿科玛法国公司 2018-03-27 CN claimed
WO-2018041286-A1 PROCESS FOR PRODUCING POTASSIUM CHLORIDE GRANULATES K+S AKTIENGESELLSCHAFT (DE) 2018-03-08 WO claimed
EP-3265535-A1 SUPER CONCENTRATE ADDITIVE SOLUTION COMPOSITION Prestone Products Corporation (US) 2018-01-10 EP claimed
CN-107250318-A Super concentrate additive solution composition 布拉斯通产品公司 2017-10-13 CN claimed
US-20160257868-A1 SUPER CONCENTRATE ADDITIVE SOLUTION COMPOSITION GOLDMAN SACHS MIDDLE MARKET LENDING CORP. II 2016-09-08 US claimed
EP-1855693-B1 AZITHROMYCIN POWDER FOR ORAL SUSPENSION COMPOSITIONS TEVA PHARMA (IL) 2009-07-29 EP claimed
EP-1855693-A1 AZITHROMYCIN POWDER FOR ORAL SUSPENSION COMPOSITIONS TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) 2007-11-21 EP claimed
WO-2006096182-A1 AZITHROMYCIN POWDER FOR ORAL SUSPENSION COMPOSITIONS TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) 2006-09-14 WO claimed
US-20060198895-A1 Azithromycin powder for oral suspension compositions TEVA PHARMACEUTICALS USA, LTD. 2006-09-07 US claimed
US-4781855-A FREE-FLOWING, CLEANING COMPOUNDS ALBRIGHT & WILSON LIMITED (GB) 1988-11-01 US claimed